Cargando…

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time poi...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadaki, Maria A., Messaritakis, Ippokratis, Fiste, Oraianthi, Souglakos, John, Politaki, Eleni, Kotsakis, Athanasios, Georgoulias, Vassilis, Mavroudis, Dimitrios, Agelaki, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831933/
https://www.ncbi.nlm.nih.gov/pubmed/33477700
http://dx.doi.org/10.3390/ijms22020925
_version_ 1783641725190799360
author Papadaki, Maria A.
Messaritakis, Ippokratis
Fiste, Oraianthi
Souglakos, John
Politaki, Eleni
Kotsakis, Athanasios
Georgoulias, Vassilis
Mavroudis, Dimitrios
Agelaki, Sofia
author_facet Papadaki, Maria A.
Messaritakis, Ippokratis
Fiste, Oraianthi
Souglakos, John
Politaki, Eleni
Kotsakis, Athanasios
Georgoulias, Vassilis
Mavroudis, Dimitrios
Agelaki, Sofia
author_sort Papadaki, Maria A.
collection PubMed
description We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC.
format Online
Article
Text
id pubmed-7831933
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78319332021-01-26 Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Papadaki, Maria A. Messaritakis, Ippokratis Fiste, Oraianthi Souglakos, John Politaki, Eleni Kotsakis, Athanasios Georgoulias, Vassilis Mavroudis, Dimitrios Agelaki, Sofia Int J Mol Sci Article We herein investigated the detection frequency and clinical relevance of circulating tumor cells (CTCs) in chemotherapy-naïve stage IIIB/IV non-small cell lung cancer (NSCLC), by using the CellSearch and real-time CEACAM5mRNA assays. Blood samples from 43 patients were obtained at different time points during first-line chemotherapy. CellSearch revealed the detection of ≥1 CTCs in 41.9%, 40.9%, and 16.7% of patients at baseline, post-1st, and post-2nd treatment cycle, respectively, and of ≥5 CTCs in 11.6%, 9.1%, and 5.6%, respectively. CEACAM5mRNA+ CTCs were detected in 29.3% and 16% of patients pre- and post-treatment, respectively. The positivity concordance between the two assays was 2.2%. CTC-detection by CellSearch (≥5 CTCs: p = 0.004), CEACAM5mRNA (p = 0.010), or by any assay (p = 0.000) was associated with disease progression. Reduced survival was demonstrated for patients harboring ≥5 CTCs (progression-free survival; PFS: p = 0.000; overall survival; OS: p = 0.009), CEACAM5mRNA+ CTCs (PFS: p = 0.043; OS: p = 0.039), and CTCs by any assay (PFS: p = 0.005; OS: p = 0.006, respectively). CTC-detection by any assay independently predicted for increased risk of relapse (hazard ratio; HR: 3.496; p = 0.001) and death (HR: 2.866; p = 0.008). CellSearch-positivity either pre-, post-1st, or post-2nd cycle, was predictive for shorter PFS (p = 0.036) compared to negativity in all time points. Persistent CEACAM5mRNA-positivity pre- and post-treatment was associated with reduced PFS (p = 0.036) and OS (p = 0.026). In conclusion, CTC detection and monitoring using the CellSearch and CEACAM5mRNA assays provides valuable and complementary clinical information for chemo-naïve advanced or metastatic NSCLC. MDPI 2021-01-18 /pmc/articles/PMC7831933/ /pubmed/33477700 http://dx.doi.org/10.3390/ijms22020925 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Papadaki, Maria A.
Messaritakis, Ippokratis
Fiste, Oraianthi
Souglakos, John
Politaki, Eleni
Kotsakis, Athanasios
Georgoulias, Vassilis
Mavroudis, Dimitrios
Agelaki, Sofia
Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title_full Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title_fullStr Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title_full_unstemmed Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title_short Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
title_sort assessment of the efficacy and clinical utility of different circulating tumor cell (ctc) detection assays in patients with chemotherapy-naïve advanced or metastatic non-small cell lung cancer (nsclc)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831933/
https://www.ncbi.nlm.nih.gov/pubmed/33477700
http://dx.doi.org/10.3390/ijms22020925
work_keys_str_mv AT papadakimariaa assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT messaritakisippokratis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT fisteoraianthi assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT souglakosjohn assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT politakieleni assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT kotsakisathanasios assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT georgouliasvassilis assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT mavroudisdimitrios assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc
AT agelakisofia assessmentoftheefficacyandclinicalutilityofdifferentcirculatingtumorcellctcdetectionassaysinpatientswithchemotherapynaiveadvancedormetastaticnonsmallcelllungcancernsclc